LIXTE Biotechnology Holdings is the title sponsor of the Good Health: Mind, Body & Soul Summit, set for February 19 at Morehouse College in Atlanta. The invitation-only event convenes leaders in healthcare, culture, science and community to promote health equity for Black men and families. LIXTE’s CEO Geordan Pursglove will spotlight the company’s lead clinical PP2A inhibitor, LB-100, which has demonstrated tolerability at doses associated with anti-cancer activity and is currently in proof-of-concept trials for ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma. Through its European subsidiary LIORA, LIXTE will also highlight development of the LiGHT System, an electronically controlled proton therapy platform designed to improve tumor targeting and patient outcomes.

LIXTE will participate in the DealFlow Discovery Conference on January 28–29 at The Borgata Hotel in Atlantic City, with CEO Geordan Pursglove conducting one-on-one investor meetings to discuss program milestones and upcoming data readouts. Attendees will learn that LB-100 has completed multiple dose-escalation cohorts showing anti-cancer activity signals, while the LiGHT System is advancing toward first human feasibility trials in Europe. The company will outline its comprehensive patent portfolio covering activation lethality in cancer biology, and detail enrollment status in its three ongoing proof-of-concept studies. Investors can schedule meetings through the conference registration portal.